Every Form 4 that Jaguar Health, Inc. (JAGX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow JAGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JAGX filings page.
Jaguar Health director John Micek received equity awards as board compensation. On December 11, 2025 he was granted stock options for 7,377 shares of common stock at an exercise price of $1.44 per share, expiring on December 11, 2035, under the 2014 Stock Incentive Plan. The options vest monthly over 12 months while he continues serving on the boards of Jaguar Health and its subsidiary Napo Therapeutics.
On the same date he also received 7,377 restricted stock units, each representing one share of common stock, which vest on December 11, 2026. After the grant he directly holds 7,430 common shares, and the vested RSU shares will be delivered on the vesting date specified in the grant notice.
Jaguar Health, Inc. reported an equity compensation award to executive Steven R. King, who serves as Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary. On December 11, 2025, he was granted 11,740 shares of common stock, bringing his directly held common stock to 11,885 shares. These shares reflect restricted stock units granted under the company’s 2014 Stock Incentive Plan and are scheduled to vest on December 11, 2026, with shares delivered on the vesting date.
On the same date, King also received a stock option for 11,740 shares of common stock with an exercise price of $1.44 per share, expiring on December 11, 2035. The option vests in equal monthly installments over 12 months from the grant date, contingent on his continued employment. Both the restricted stock units and options were approved by the board of directors as part of the company’s stock incentive program, and were reported as directly owned.
Jaguar Health, Inc. reported an equity compensation grant to Chief Executive Officer and President Lisa A. Conte, who is also a director. On December 11, 2025, she received 28,592 restricted stock units of common stock at a price of $0, increasing her directly owned common shares to 29,258. Each unit represents one share and will vest on December 11, 2026, with shares delivered on that date.
On the same date, she was granted stock options for 28,592 shares of common stock with an exercise price of $1.44 per share, expiring on December 11, 2035. These options vest ratably on a monthly basis over 12 months from the grant date, contingent on her continued employment, and were issued under the company’s 2014 Stock Incentive Plan.
Jaguar Health, Inc. reported an equity award to officer Jonathan S. Wolin, who serves as Chief of Staff, Chief Compliance Officer and General Counsel. On December 11, 2025, he received 11,740 shares of common stock in the form of restricted stock units at a price of $0, granted under the company’s 2014 Stock Incentive Plan. These restricted stock units each represent one share of voting common stock and are scheduled to vest on December 11, 2026, with shares delivered on the vesting date as provided in the grant notice.
On the same date, he was also granted a stock option for 11,740 shares of common stock with an exercise price of $1.44 per share, expiring on December 11, 2035. The option vests ratably on a monthly basis over 12 months from the grant date, contingent on his continued employment. After these grants, he directly beneficially owned 11,938 shares of common stock and options covering 11,740 shares.
Jaguar Health Chief Scientific Officer Pravin Chaturvedi reported new equity awards in the company’s stock. On December 11, 2025, he received 11,740 restricted stock units, each representing a right to one share of Jaguar Health voting common stock. These restricted stock units vest on December 11, 2026, when the underlying shares are scheduled to be delivered.
On the same date, he was also granted a stock option covering 11,740 shares of common stock at an exercise price of $1.44 per share, expiring on December 11, 2035. The option vests ratably on a monthly basis over 12 months from the grant date, as long as he remains employed, and both awards were granted under Jaguar Health’s 2014 Stock Incentive Plan. Following the grant, he beneficially owned 11,938 shares of common stock directly, plus the 11,740 stock options. The filing also notes a 25-for-1 reverse stock split of Jaguar’s voting common stock effective March 24, 2025.
Jaguar Health director James J. Bochnowski reported new equity awards. On December 11, 2025, he received 6,363 restricted stock units and a stock option for 6,363 shares of common stock, granted under the company’s 2014 Stock Incentive Plan.
Each restricted stock unit represents one share of voting common stock and will vest on December 11, 2026, with shares delivered on that date. The stock option has an exercise price of $1.44 per share, vests ratably on a monthly basis over 12 months from the grant date while he continues serving on the board, and expires on December 11, 2035.
Following the grant, Bochnowski beneficially owned 6,415 shares of Jaguar Health common stock directly.
Jaguar Health director Jonathan B. Siegel reported receiving new equity awards under the company’s 2014 Stock Incentive Plan. The filing shows 7,377 restricted stock units and a stock option covering 7,377 shares of common stock, both granted on 12/11/2025 at no cost for the awards themselves, with the option carrying a $1.44 exercise price and expiring on 12/11/2035.
The restricted stock units are scheduled to vest on 12/11/2026, while the options vest ratably on a monthly basis over 12 months from the grant date, contingent on his continued board service at Jaguar Health and its subsidiary Napo Therapeutics, S.p.A. Following these grants, he directly beneficially owned 7,423 shares of Jaguar Health common stock.
Jaguar Health, Inc. director Anula Jayasuriya received equity awards consisting of 5,870 restricted stock units and stock options covering 5,870 shares of common stock, approved by the board on December 11, 2025 under the company’s 2014 Stock Incentive Plan.
Each restricted stock unit represents a right to receive one share and vests on December 11, 2026, while the options have a $1.44 exercise price, vest monthly over 12 months from the grant date, and expire on December 11, 2035. Following these grants, she beneficially owns 5,916 shares of common stock and 5,870 stock options, held directly.
Jaguar Health, Inc. reported that its Chief Financial Officer, Carol R. Lizak, received new equity awards on December 11, 2025.
The awards include 11,740 restricted stock units, each representing a contingent right to receive one share of voting common stock for $0 consideration, with beneficial ownership of common stock reported as 11,911 shares after the transaction. She also received stock options to purchase 11,740 shares of common stock at an exercise price of $1.44 per share, expiring on December 11, 2035.
The grants were made under the company’s 2014 Stock Incentive Plan. The restricted stock units vest on December 11, 2026, and vested shares will be delivered on that vesting date, while the options vest in equal monthly installments over 12 months from the grant date, subject to continued employment.